Responses
Clinical/translational cancer immunotherapy
Original research
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
